Sanofi's bowel cancer drug Zaltrap is not cost-effective, NICE says

06/21/2013 | Reuters

The U.K. National Institute for Health and Clinical Excellence rejected the use of Sanofi's Zaltrap to treat bowel cancer because of its expense. The drug is not cost-effective despite the discount offered by Sanofi, NICE said. The drug has also taken the spotlight in the U.S. due to its high price.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC